For patients with intermediate or lower risk essential thrombocythemia with plt >1000 but no symptoms, do you favor aspirin only therapy or aspirin and cytoreduction?

Recent data without increased cumulative incidence of bleeding in ET patients with plt >1000. Has your practice changed to use cytoreduction less frequently? Have your frequency for monitoring for acquired vWD changed?

Answer from: at Academic Institution

First, the wrong question is being asked. The correct question is, what is the proof that the low-risk, intermediate-risk, or high-risk ET classification has any validity? My answer would be that this classification has no validity. Whether it is based on the IPSET scoring system or one of the other...

Please select the option that best describes you:

For patients with intermediate or lower risk essential thrombocythemia with plt >1000 but no symptoms, do you favor aspirin only therapy or aspirin and cytoreduction?

Related Questions